# Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

> **NCT01746784** · PHASE1 · COMPLETED · sponsor: **Nivalis Therapeutics, Inc.** · enrollment: 66 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** N6022
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT01746784
- **Lead sponsor:** Nivalis Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-04
- **Final completion:** 2014-05
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2014-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01746784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01746784, "Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01746784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*